[go: up one dir, main page]

AR069078A1 - Derivados de piridina y pirazina - Google Patents

Derivados de piridina y pirazina

Info

Publication number
AR069078A1
AR069078A1 ARP080104644A ARP080104644A AR069078A1 AR 069078 A1 AR069078 A1 AR 069078A1 AR P080104644 A ARP080104644 A AR P080104644A AR P080104644 A ARP080104644 A AR P080104644A AR 069078 A1 AR069078 A1 AR 069078A1
Authority
AR
Argentina
Prior art keywords
alkyl
alkoxy
amino
con
hydroxy
Prior art date
Application number
ARP080104644A
Other languages
English (en)
Inventor
Craig S Harris
Gary Fairley
Gilles Ouvry
Jon J Winter
Benedicte Delouvrie
Justin F Bower
Marie P Lambert
Bernard C Barlaam
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR069078A1 publication Critical patent/AR069078A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Composiciones farmacéuticas que los contienen y su uso en la elaboracion de un medicamento en el tratamiento de trastornos de proliferacion celular. Reivindicacion 1: Un compuesto caracterizado porque responde a la formula (1) donde W es CH o N; J es O o S; cada uno de G1, G2, G3 y G4 se selecciona entre CH y N con la condicion de que no más de dos de G1, G2, G3 y G4 representan N; el Anillo A se selecciona entre (i) fenilo sustituido con R1 y sustituido opcionalmente con hasta tres grupos R2; o (ii) un anillo heteroarilo monocíclico de 5 o 6 miembros con hasta tres heteroátomos del anillo que se seleccionan entre oxígeno, nitrogeno y azufre, donde dicho anillo está sustituido con R1 y opcionalmente está sustituido con hasta tres grupos R2; o (iii) un sistema de anillos bicíclico de 8, 9 o 10 miembros, donde dicho sistema de anillos bicíclico opcionalmente tiene hasta tres heteroátomos del anillo que se seleccionan entre oxígeno, nitrogeno y azufre y está sustituido opcionalmente por R1 y opcionalmente está sustituido con hasta tres grupos R2; R1 es un grupo con la formula: R4-X1- donde X1 es un enlace directo o se selecciona entre O, S, SO, SO2, N(R5), CO, CH(OR5), CON(R5), N(R5)CO, N(R5)CON(R5), SO2N(R5), N(R5)SO2, C(R5)2O, OC(R5)2, C(R5)2S, SC(R5)2, C(R5)2, C(R5)2N(R5) y N(R5)C(R5)2, donde cada R5 se selecciona independientemente entre hidrogeno, (C1-8)alquilo C1-8, hidroxi-alquilo C1-6, alcoxi C1-6-alquilo C1-6, ciano-alquilo C1-6, halogeno-alquilo C1-6, di-[alquil C1-6]amino-alquilo C1-6, alquilamino C1-6-alquilo C1-6 o amino-alquilo C1-6, y cuando X1 es un enlace directo o se selecciona entre CH(OR5), C(R5)2O, C(R5)2S, C(R5)2 o C(R5)2N(R5), donde R5 tiene cualquiera de los significados que se definieron anteriormente;, R4 es hidroxi-alquilo C1-6, alcoxi C1-6-alquilo C1-6, R5-S, R5-S(O), R5-SO2, R5-SO2-O, R5-S-alquilo C1-6, R5-S(O)-alquilo C1-6, R5-SO2-alquilo C1-6, N,N-di(R5)sulfamoilo, N,N-di-(R5)sulfamoil-alquilo C1-6, R5-SO2N(R5), R5-SO2N(R5)-alquilo C1-6, R5-CON(R5), R5O-CON(R5), R5-CON(R5)-alquilo C1-6, R5O-CON(R5)-alquilo C1-6, (R5)2N-SO2N(R5), (R5)2N-SO2N(R5)-alquilo C1-6, (R5)2N-CON(R5), (R5)2N-CON(R5)-alquilo C1-6, R5-CO, R5-CO-alquilo C1-6, R5O-CO-alquilo C1-6, (R5)2NCO, (R5)2NCO-alquilo C1-6, (R5)2N-COO, (R5)2NCOO-alquilo C1-6, ciano, amino, (R6)-amino, di-(R6)-amino, amino-alquilo C1-6, (R6)-amino-alquilo C1-6 o di(R6)-amino-alquilo C1-6, donde cada R6 que está presente es alquilo C1-6 sustituido opcionalmente con 1, 2 o 3 sustituyentes que se seleccionan independientemente entre halogeno, ciano, hidroxi y alcoxi C1-6; y cuando X1 se selecciona entre O, S, SO, SO2, N(R5), CO, CON(R5), N(R5)CO, N(R5)CON(R5), SO2N(R5), N(R5)SO2, OC(R5)2, SC(R5)2 y N(R5)C(R5)2, donde R5 tiene cualquiera de los significados que se definieron anteriormente, R4 es hidroxi-alquilo C1-6, alcoxi C1-6-alquilo C1-6, R5-S-alquilo C1-6, R5-S(O)-alquilo C1-6, R5-SO2-alquilo C1-6, N,N-di-(R5)sulfamoil-alquilo C1-6, R5-SO2N(R5)-alquilo C1-6, R5-CON(R5)-alquilo C1-6, R5O-CON(R5)-alquilo C1-6, (R5)2N-SO2N(R5)-alquilo C1-6, (R5)2N-CON(R5)-alquilo C1-6, R5-CO, R5-CO-alquilo C1-6, R5O-CO, R5O-CO-alquilo C1-6, (R5)2NCO, (R5)2NCO-alquilo C1-6, (R5)2NCOO-alquilo C1-6, amino-alquilo C1-6, (R6)-amino-alquilo C1-6 o di-(R6)-amino-alquilo C1-6, donde cada R6 que está presente es alquilo C1-6 sustituido opcionalmente con 1, 2 o 3 sustituyentes que se seleccionan independientemente entre halogeno, ciano, hidroxi y alcoxi C1-6; o R1 es un grupo con la formula: Q1-X2- donde X2 es un enlace directo o se selecciona entre O, S, SO, SO2, N(R7), N[C(O)R7], N[C(O)N(R7)2], N[C(O)OR7], N[SO2-N(R7)2], CO, CH(OR7), CON(R7), N(R7)CO, N(R7)CON(R7), SO2N(R7), N(R7)SO2, O-SO2, SO2O, C(R7)2O, OC(R7)2, C(R7)2S, SC(R7)2, C(R7)2, C(R7)2N(R7) y N(R7)C(R7)2, donde cada R7 se selecciona independientemente entre hidrogeno, alquilo C1-8, hidroxi-alquilo C1-6, alcoxi C1-6-alquilo C1-6, ciano-alquilo C1-6, halogenoalquilo C1-6, di-(R8)amino-alquilo C1-6, (R8)-amino-alquilo C1-6 o amino-alquilo C1-6, donde R8 es alquilo C1-6 sustituido opcionalmente con 1, 2 o 3 sustituyentes que se seleccionan independientemente entre halogeno, ciano, hidroxi y alcoxi C1-6; y Q1 es arilo, aril-alquilo C1-6, cicloalquilo C3-8, cicloalquil C3-8-alquilo C1-6, heterociclilo, heterociclil-alquilo C1-6, heteroarilo o heteroaril-alquilo C1-6, donde cualquier grupo arilo o cicloalquilo C3-8 en un sustituyente R1 lleva 1, 2 o 3 sustituyentes y cualquier grupo heterociclilo o heteroarilo en un sustituyente R1 opcionalmente tiene 1, 2 o 3 sustituyentes, donde dichos sustituyentes se seleccionan independientemente entre halogeno, trifluorometilo, ciano, nitro, hidroxi, amino, carboxi, carbamoilo, ureido, alquilo C1-8, alquenilo C2-8, alquinilo C2-8, alcoxi C1-6, halogeno-alcoxi C1-6, hidroxi-alquilo C1-6, alcoxi C1-6-alquilo C1-6, alquilsulfonil C1-6-alquilo C1-6, ciano-alquilo C1-6, halogeno-alquilo C1-6, amino-alquilo C1-6, alquilamino C1-6-alquilo C1-6, di-[alquil C1-6]amino-alquilo C1-6, alqueniloxi C2-6, alquiniloxi C2-6, alquiltio C1-6, alquilsulfinilo C1-6, alquilsulfonilo C1-6, alquilamino C1-6, di-[alquil C1-6]amino, alcoxicarbonilo C1-6, alcanoilo C2-6, hidroxi-alcanoilo C2-6, alcoxi C1-6-alcanoilo C2-6, alcanoiloxi C2-6, N-alquilcarbamoilo C1-6, N,N-di-[alquil C1-6]carbamoilo, carbamoil-alquilo C1-6, N-alquil-carbamoil C1-6-alquilo C1-6, N,N-di-[alquil C1-6]carbamoil-alquilo C1-6, alcanoilamino C1-6, N-alquil C1-6-alcanoilamino C1-6, N-alquilureido C1-6, N'-alquilureido C1-6, N',N'-di-[alquil C1-6]ureido, N,N'-di-[alquil C1-6]ureido, N,N',N'-tri-[alquil C1-6]ureido, N-alquilsulfamoilo C1-6, N,N-di-[alquil C1-6]sulfamoilo, alcansulfonilamino C1-6, N-alquil C1-6-alcansulfonilamino C1-6, alcoxi C1-6-alcoxicarbonilo C1-6, alquilamino C1-6-alcanoilo C2-6, di-[alquil C1-6]amino-alcanoilo C2-6, alcanoilamino C1-6-alcanoilo C2-6, alcoxi C1-6-alcoxi C1-6-alcanoilo C2-6, heterociclilo, heterociclilalquilo C1-6, heteroarilo o heteroaril-alquilo C1-6 y algun grupo heterociclilo dentro de un sustituyente R1 opcionalmente tiene 1 o 2 sustituyentes oxo; donde, cualquier CH, CH2, o CH3 en cualquiera de los grupos alquilo que esté presente en la definicion de R4 que se conecta a X1 o que esté presente en la definicion de Q1 que se conecta a X2, opcionalmente tiene un grupo hidroxi o ciano y opcionalmente tiene hasta tres grupos halogenos, y se puede reemplazar opcionalmente por un átomo que se selecciona entre O, S o N o un grupo SO2 y los átomos de carbono adyacentes en una cadena alquilo opcionalmente pueden estar separados por la insercion en la cadena de un grupo CsC; cada uno de los grupos R2 puede ser igual o diferente y se selecciona entre halogeno, ciano, hidroxi, amino, alquilo C1-8, alquenilo C2-8, alquinilo C2-8, alcoxi C1-6, alqueniloxi C2-6, alquiniloxi C2-6, halogeno-alcoxi C1-6, alquiltio C1-6, alquilsulfinilo C1-6, alquilsulfonilo C1-6, alquilamino C1-6, di-[alquil C1-6]amino, alcoxicarbonilo C1-6, alcanoilo C2-6, alcanoiloxi C2-6, carbamoilo, N-alquilcarbamoilo C1-6, N,N-di-{alquil C1-6}carbamoilo, alcanoilamino C1-6, N-alquil C1-6-alcanoilamino C1-6, alcoxi C1-6-alquilo C1-6, hidroxi-alquilo C1-6, amino-alquilo C1-6, alquilamino C1-6-alquilo C1-6, di-{alquil C1-6]amino-alquilo C1-6, alcoxi C1-6-alcoxi C1-6, hidroxi-alcoxi C1-6, amino-alcoxi C1-6, alquilamino C1-6-alcoxi C1-6 y di-[alquil C1-6]amino-alcoxi C1-6; n es 0, 1, 2 o 3 y, cuando n es 2 o 3, cada uno de los grupos R3 puede ser igual o diferente, y cada uno de los grupos R3 presente se selecciona entre hidrogeno, halogeno, amino, ciano, sulfamoilo, OR9, N-alquil-sulfamoilo C1-6, N,N-di-[alquil C1-6]sulfamoilo, trifluorometilo, alquilo C1-8, alquenilo C2-8, alquinilo C2-8, alcoxi C1-6, alcoxicarbonilo C1-6, halogeno-alcoxi C1-6, carbamoilo, N-alquilcarbamoilo C1-6, N,N-di-[alquil C1-6]carbamoilo, alcanoilamino C1-6, alquiltio C1-6, alquilsulfinilo C1-6, alquilsulfonilo C1-6, hidroxi-alquilo C1-6, alcoxi C1-6-alquilo C1-6, alcanoilo C2-6, alcansulfonilamino C1-6, amino-alquilo C1-6, alquilamino C1-6-alquilo C1-6, di-[alquil C1-6]amino-alquilo C1-6, alcoxi C1-6-alcoxi C1-6, hidroxi-alcoxi C1-6, amino-alcoxi C1-6, alquilamino C1-6-alcoxi C1-6 y di-{alquil C1-6]amino-alcoxi C1-6, donde R9 es fluoro-alquilo C1-6, arilo, aril-alquilo C1-6, heterociclilo, heterociclil-alquilo C1-6, heteroarilo o heteroaril-alquilo C1-6, donde cualquier grupo arilo, heterociclilo o heteroarilo dentro de la definicion de R9 opcionalmente tiene 1, 2 o 3 sustituyentes que se seleccionan independientemente entre halogeno, fluoroalquilo C1-6, oxo, ciano, hidroxi, amino, carboxi, carbamoilo, alquilo C1-8, alquenilo C2-8, alquinilo C2-8 o alcoxi C1-6; o una sal del mismo aceptable para uso farmacéutico.
ARP080104644A 2007-10-25 2008-10-24 Derivados de piridina y pirazina AR069078A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07301491 2007-10-25
EP07305005 2007-12-21
EP08305180 2008-05-19

Publications (1)

Publication Number Publication Date
AR069078A1 true AR069078A1 (es) 2009-12-30

Family

ID=40580139

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080104644A AR069078A1 (es) 2007-10-25 2008-10-24 Derivados de piridina y pirazina

Country Status (18)

Country Link
US (1) US8017611B2 (es)
EP (1) EP2215085B1 (es)
JP (1) JP2011500778A (es)
KR (1) KR20100089090A (es)
CN (1) CN101910158A (es)
AR (1) AR069078A1 (es)
AT (1) ATE523508T1 (es)
AU (1) AU2008315746A1 (es)
CA (1) CA2703653A1 (es)
CL (1) CL2008003188A1 (es)
CO (1) CO6270364A2 (es)
EC (1) ECSP10010197A (es)
IL (1) IL205108A0 (es)
MX (1) MX2010004491A (es)
PE (1) PE20091116A1 (es)
TW (1) TW200920367A (es)
UY (1) UY31430A1 (es)
WO (1) WO2009053737A2 (es)

Families Citing this family (142)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007026341A1 (de) 2007-06-06 2008-12-11 Merck Patent Gmbh Benzoxazolonderivate
DE102007032507A1 (de) 2007-07-12 2009-04-02 Merck Patent Gmbh Pyridazinonderivate
DE102007061963A1 (de) 2007-12-21 2009-06-25 Merck Patent Gmbh Pyridazinonderivate
EP2265270A1 (en) 2008-02-04 2010-12-29 OSI Pharmaceuticals, Inc. 2-aminopyridine kinase inhibitors
AR070317A1 (es) 2008-02-06 2010-03-31 Osi Pharm Inc Furo (3,2-c) piridina y tieno (3,2-c) piridinas
JP2011511078A (ja) * 2008-02-06 2011-04-07 レアド トヘラペウトイクス，インコーポレーテッド ポリ（ａｄｐリボース）ポリメラーゼ（ｐａｒｐ）のベンズオキサゾールカルボキサミド阻害剤
DE102008019907A1 (de) 2008-04-21 2009-10-22 Merck Patent Gmbh Pyridazinonderivate
DE102008028905A1 (de) 2008-06-18 2009-12-24 Merck Patent Gmbh 3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo[4,3-b]pyridazinderivate
CN102264721B (zh) 2008-11-10 2015-12-09 沃泰克斯药物股份有限公司 用作atr激酶抑制剂的化合物
TWI396689B (zh) 2008-11-14 2013-05-21 Amgen Inc 作為磷酸二酯酶１０抑制劑之吡衍生物
UY32285A (es) * 2008-12-02 2010-06-30 Du Pont Compuestos heterocíclicos fungicidas
CN106518856B (zh) 2008-12-19 2020-04-28 沃泰克斯药物股份有限公司 用作atr激酶抑制剂的化合物
MY160526A (en) 2008-12-22 2017-03-15 Merck Patent Gmbh Novel polymorphic forms of 6-(1-methyl-1h-pyrazol-4-yl)-2-{3-[5-(2-morpholin-4-yl-ethoxy)-pyrimidin-2-yl]-benzyl}-2h-pyridazin-3-one dihydrogenphosphate and processes of manufacturing thereof
DE102009033208A1 (de) 2009-07-15 2011-01-20 Merck Patent Gmbh Aminopyridinderivate
US20110118275A1 (en) * 2009-11-13 2011-05-19 Astrazeneca Ab OXAZOLO[4,5-c]PYRIDINE SUBSTITUTED PYRAZINE
US8969356B2 (en) 2010-05-12 2015-03-03 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
JP2013526540A (ja) 2010-05-12 2013-06-24 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｔｒキナーゼ阻害剤として有用な化合物
US9062008B2 (en) 2010-05-12 2015-06-23 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US8962631B2 (en) 2010-05-12 2015-02-24 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
MX2012013082A (es) * 2010-05-12 2013-05-09 Vertex Pharma Derivados de 2-aminopiridina utiles como iinhibidores de cinasa atr.
SG185524A1 (en) * 2010-05-12 2012-12-28 Vertex Pharma Compounds useful as inhibitors of atr kinase
UY33452A (es) 2010-06-16 2012-01-31 Bayer Schering Pharma Ag Triazolopiridinas sustituidas
US8623869B2 (en) 2010-06-23 2014-01-07 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US20130315895A1 (en) 2010-07-01 2013-11-28 Takeda Pharmaceutical Company Limited COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
WO2012121939A2 (en) * 2011-03-04 2012-09-13 Locus Pharmaceuticals, Inc. Aminopyrazine compounds
CN102718745A (zh) * 2011-03-30 2012-10-10 中国科学院上海药物研究所 新型胺基吡啶类化合物、其制备方法、包含此类化合物的药物组合物及其用途
CA2832100A1 (en) 2011-04-05 2012-10-11 Vertex Pharmaceuticals Incorporated Aminopyrazine compounds useful as inhibitors of tra kinase
WO2012138809A1 (en) * 2011-04-05 2012-10-11 Dawei Zhang Heterocyclic compounds as kinase inhibitors
US9273029B2 (en) 2011-05-23 2016-03-01 Merck Patent Gmbh Pyridine-and pyrazine derivatives
DK2714668T3 (en) 2011-05-23 2017-03-20 Merck Patent Gmbh thiazole
JP2014520161A (ja) 2011-06-22 2014-08-21 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｔｒキナーゼ阻害剤として有用な化合物
US9309250B2 (en) 2011-06-22 2016-04-12 Vertex Pharmaceuticals Incorporated Substituted pyrrolo[2,3-b]pyrazines as ATR kinase inhibitors
US9096602B2 (en) 2011-06-22 2015-08-04 Vertex Pharmaceuticals Incorporated Substituted pyrrolo[2,3-B]pyrazines as ATR kinase inhibitors
US9226923B2 (en) * 2011-07-27 2016-01-05 Nanjing Allgen Pharma Co. Ltd. Spirocyclic molecules as protein kinase inhibitors
DE102011112978A1 (de) 2011-09-09 2013-03-14 Merck Patent Gmbh Benzonitrilderivate
CA2850566C (en) 2011-09-30 2022-05-03 Vertex Pharmaceuticals Incorporated Process for making 4-[chloro-n-hydroxycarbonimidoyl]phenyl derivative
EP3733185B1 (en) 2011-09-30 2022-12-07 Vertex Pharmaceuticals Incorporated Treating non-small cell lung cancer with atr inhibitors
WO2013049719A1 (en) 2011-09-30 2013-04-04 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
CN103958507A (zh) 2011-09-30 2014-07-30 沃泰克斯药物股份有限公司 可用作atr激酶抑制剂的化合物
WO2013049720A1 (en) 2011-09-30 2013-04-04 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
CN103087050A (zh) * 2011-10-28 2013-05-08 山东轩竹医药科技有限公司 芳基激酶抑制剂
WO2013071088A1 (en) 2011-11-09 2013-05-16 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
WO2013071090A1 (en) 2011-11-09 2013-05-16 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
US8841449B2 (en) 2011-11-09 2014-09-23 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US8846918B2 (en) 2011-11-09 2014-09-30 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
WO2013071093A1 (en) 2011-11-09 2013-05-16 Vertex Pharmaceuticals Incorporated Pyrazine compounds useful as inhibitors of atr kinase
DE102011119127A1 (de) 2011-11-22 2013-05-23 Merck Patent Gmbh 3-Cyanaryl-1H-pyrrolo[2.3-b]pyridin-Derivate
RS55728B1 (sr) * 2012-01-31 2017-07-31 Daiichi Sankyo Co Ltd Derivat piridona
HRP20161578T1 (hr) 2012-02-09 2016-12-30 Merck Patent Gmbh Derivati furo[3, 2-b]piridina kao inhibitori tbk1 i ikk
WO2013148537A1 (en) * 2012-03-29 2013-10-03 Ning Xi Substituted spirobicyclic compounds and methods of use
EP2833973B1 (en) 2012-04-05 2017-09-13 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase and combination therapies thereof
US9096579B2 (en) 2012-04-20 2015-08-04 Boehringer Ingelheim International Gmbh Amino-indolyl-substituted imidazolyl-pyrimidines and their use as medicaments
WO2013162061A1 (ja) * 2012-04-26 2013-10-31 第一三共株式会社 二環性ピリミジン化合物
CN107652289B (zh) 2012-06-13 2020-07-21 因塞特控股公司 作为fgfr抑制剂的取代的三环化合物
KR101245559B1 (ko) * 2012-06-29 2013-03-22 한국화학연구원 신규 다중치환 벤즈옥사졸로 치환된 피리딘 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 이상세포 성장 질환의 예방 및 치료용 약학적 조성물
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US8999632B2 (en) 2012-10-04 2015-04-07 Vertex Pharmaceuticals Incorporated Method for measuring ATR inhibition mediated increases in DNA damage
US8912198B2 (en) 2012-10-16 2014-12-16 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
DK3418281T3 (da) 2012-12-07 2020-12-07 Vertex Pharma Pyrazolo[1,5-a]pyrimidiner, der er anvendelige som inhibitorer af atr-kinase til behandling af cancersygdomme
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
MX2015009270A (es) * 2013-01-18 2015-10-30 Hoffmann La Roche Pirazoles sustituidos en posicion 3 y uso de los mismos como inhibidores de la cinasa cremallera de leucinas dual (dlk).
AU2014208964B2 (en) 2013-01-23 2016-09-01 Astrazeneca Ab Chemical compounds
EP2952510B1 (en) * 2013-02-02 2018-12-26 Chia Tai Tianqing Pharmaceutical Group Co.,Ltd Substituted 2-aminopyridine protein kinase inhibitor
WO2014160203A2 (en) 2013-03-14 2014-10-02 The Brigham And Women's Hospital, Inc. Bmp inhibitors and methods of use thereof
JP2016512815A (ja) 2013-03-15 2016-05-09 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ａｔｒキナーゼの阻害剤として有用な縮合ピラゾロピリミジン誘導体
JP6449244B2 (ja) 2013-04-19 2019-01-09 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｆｇｆｒ抑制剤としての二環式複素環
CN105916506B (zh) 2013-11-20 2020-01-07 圣诺康生命科学公司 作为tam家族激酶抑制剂的喹唑啉衍生物
WO2015081257A2 (en) 2013-11-27 2015-06-04 Signalchem Lifesciences Corporation Aminopyridine derivatives as tam family kinase inhibitors
PT3077397T (pt) 2013-12-06 2020-01-22 Vertex Pharma Composto de 2-amino-6-fluoro-n-[5-fluoro-piridin-3-il]pirazolo[1,5-a]pirimidin-3-carboxamida útil como inibidor da atr quinase, a sua preparação, diferentes formas sólidas e derivados radiomarcados do mesmo
JP2017514793A (ja) * 2014-03-26 2017-06-08 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． Ｂｍｐ阻害用組成物及びｂｍｐ阻害方法
BR112016024484A2 (pt) 2014-04-24 2017-08-15 Novartis Ag derivados de aminopiridina como inibidores de fosfatidilinositol 3-quinase
JP6433509B2 (ja) 2014-04-24 2018-12-05 ノバルティス アーゲー ホスファチジルイノシトール３−キナーゼ阻害薬としてのアミノピラジン誘導体
PL3134395T3 (pl) 2014-04-24 2018-07-31 Novartis Ag Pochodne pirazyny jako inhibitory 3-kinazy fosfatydyloinozytolu
KR102575125B1 (ko) 2014-06-05 2023-09-07 버텍스 파마슈티칼스 인코포레이티드 Atr 키나제의 저해제로서 유용한 2-아미노-6-플루오로-n-[5-플루오로-피리딘-3-일]-피라졸로[1,5-a]피리미딘-3-카복스아미드 화합물의 방사성표지된 유도체, 상기 화합물의 제조 및 이의 다양한 고체 형태
DK3157566T3 (da) 2014-06-17 2019-07-22 Vertex Pharma Fremgangsmåde til behandling af cancer under anvendelse af en kombination chk1- og atr-inhibitorer
TWI690525B (zh) 2014-07-07 2020-04-11 日商第一三共股份有限公司 具有四氫吡喃基甲基之吡啶酮衍生物及其用途
US10513521B2 (en) 2014-07-15 2019-12-24 The Brigham And Women's Hospital, Inc. Compositions and methods for inhibiting BMP
US9359336B2 (en) 2014-10-09 2016-06-07 Allergan, Inc. Heterocycle-substituted pyridyl benzothiophenes as kinase inhibitors
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
TR201815071T4 (tr) * 2014-12-02 2018-11-21 Bayer Cropscience Ag Zararlılarla mücadele maddesi olarak bisiklik bileşikler.
US10398774B2 (en) 2014-12-09 2019-09-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Human monoclonal antibodies against AXL
ES2751669T3 (es) 2015-02-20 2020-04-01 Incyte Corp Heterociclos bicíclicos como inhibidores FGFR
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
WO2016135041A1 (en) 2015-02-26 2016-09-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Fusion proteins and antibodies comprising thereof for promoting apoptosis
WO2016183071A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Hetero-tricyclic compounds and their use for the treatment of cancer
WO2016208744A1 (ja) 2015-06-25 2016-12-29 大鵬薬品工業株式会社 線維症治療剤
WO2017027717A1 (en) 2015-08-12 2017-02-16 Incyte Corporation Bicyclic fused pyrimidine compounds as tam inhibitors
WO2017035366A1 (en) 2015-08-26 2017-03-02 Incyte Corporation Pyrrolopyrimidine derivatives as tam inhibitors
MX395066B (es) 2015-09-30 2025-03-24 Vertex Pharma Método para tratar cáncer usando una combinación de agentes que dañan el adn e inhibidores de proteína relacionada con ataxia telangiectasia y rad3 (atr).
TW201718581A (zh) 2015-10-19 2017-06-01 英塞特公司 作為免疫調節劑之雜環化合物
SG10202004618TA (en) 2015-11-19 2020-06-29 Incyte Corp Heterocyclic compounds as immunomodulators
US20170174671A1 (en) 2015-12-17 2017-06-22 Incyte Corporation Heterocyclic compounds as immunomodulators
SI3394033T1 (sl) 2015-12-22 2021-03-31 Incyte Corporation Heterociklične spojine kot imunomodulatorji
WO2017146236A1 (ja) 2016-02-26 2017-08-31 小野薬品工業株式会社 Ａｘｌ阻害剤と免疫チェックポイント阻害剤とを組み合わせて投与することを特徴とする癌治療のための医薬
HUE064656T2 (hu) 2016-03-28 2024-04-28 Incyte Corp Pirrolotriazin vegyületek mint TAM inhibitorok
AR108396A1 (es) 2016-05-06 2018-08-15 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
MA45116A (fr) 2016-05-26 2021-06-02 Incyte Corp Composés hétérocycliques comme immunomodulateurs
ES2927984T3 (es) 2016-06-20 2022-11-14 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
ES2930092T3 (es) 2016-07-14 2022-12-07 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
US20180057486A1 (en) 2016-08-29 2018-03-01 Incyte Corporation Heterocyclic compounds as immunomodulators
KR102279347B1 (ko) * 2016-12-15 2021-07-21 한국생명공학연구원 피리딘계 화합물을 유효성분으로 함유하는 dyrk 관련 질환의 예방 또는 치료용 약학적 조성물
WO2018111049A1 (ko) * 2016-12-15 2018-06-21 한국생명공학연구원 피리딘계 화합물을 유효성분으로 함유하는 dyrk 관련 질환의 예방 또는 치료용 약학적 조성물
EP3558963B1 (en) 2016-12-22 2022-03-23 Incyte Corporation Bicyclic heteroaromatic compounds as immunomodulators
WO2018119221A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Pyridine derivatives as immunomodulators
WO2018119236A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Triazolo[1,5-a]pyridine derivatives as immunomodulators
MX391981B (es) 2016-12-22 2025-03-21 Incyte Corp Derivados de benzooxazol como inmunomoduladores.
CA3053739C (en) 2017-02-15 2023-02-14 Taiho Pharmaceutical Co., Ltd. Pharmaceutical composition
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
WO2019039525A1 (ja) 2017-08-23 2019-02-28 小野薬品工業株式会社 Ａｘｌ阻害剤を有効成分として含むがん治療剤
JP7074760B2 (ja) 2017-09-08 2022-05-24 大鵬薬品工業株式会社 抗腫瘍剤及び抗腫瘍効果増強剤
KR102739325B1 (ko) 2017-09-27 2024-12-09 인사이트 코포레이션 Tam 억제제로서 유용한 피롤로트리아진 유도체의 염
JP7223998B2 (ja) 2017-10-13 2023-02-17 小野薬品工業株式会社 Ａｘｌ阻害剤を有効成分として含む固形がん治療剤
WO2019186358A1 (en) * 2018-03-26 2019-10-03 Novartis Ag 3-hydroxy-n-(3-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)pyrrolidine-1-carboxamide derivatives
SMT202300065T1 (it) 2018-03-30 2023-05-12 Incyte Corp Composti eterociclici come immunomodulatori
PE20210919A1 (es) 2018-05-04 2021-05-19 Incyte Corp Sales de un inhibidor de fgfr
CN119241541A (zh) 2018-05-04 2025-01-03 因赛特公司 Fgfr抑制剂的固体形式和其制备方法
PL3790877T3 (pl) 2018-05-11 2023-06-12 Incyte Corporation Pochodne tetrahydroimidazo[4,5-c]pirydyny jako immunomodulatory pd-l1
ES3031110T3 (en) 2018-06-29 2025-07-04 Incyte Corp Formulations of an axl/mer inhibitor
EP3856345A1 (en) 2018-09-29 2021-08-04 Novartis AG Process of manufacture of a compound for inhibiting the activity of shp2
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
KR102200032B1 (ko) * 2019-03-13 2021-01-08 전남대학교산학협력단 호흡기 질환의 예방 또는 치료용 조성물
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
WO2021030162A1 (en) 2019-08-09 2021-02-18 Incyte Corporation Salts of a pd-1/pd-l1 inhibitor
IL291471B2 (en) 2019-09-30 2025-04-01 Incyte Corp Pyrimido[3,2–D]pyrimidine compounds as immunomodulators
WO2021067374A1 (en) 2019-10-01 2021-04-08 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
GEP20247679B (en) 2019-10-14 2024-10-10 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
CN114829366A (zh) 2019-11-11 2022-07-29 因赛特公司 Pd-1/pd-l1抑制剂的盐及结晶形式
CA3163875A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
IL293001A (en) 2019-12-04 2022-07-01 Incyte Corp Derivatives of fgfr repressors
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
AU2021230385A1 (en) 2020-03-06 2022-09-22 Incyte Corporation Combination therapy comprising AXL/MER and PD-1/PD-L1 inhibitors
TW202233615A (zh) 2020-11-06 2022-09-01 美商英塞特公司 Ｐｄ—１／ｐｄ—ｌ１抑制劑之結晶形式
WO2022099018A1 (en) 2020-11-06 2022-05-12 Incyte Corporation Process of preparing a pd-1/pd-l1 inhibitor
US11866434B2 (en) 2020-11-06 2024-01-09 Incyte Corporation Process for making a PD-1/PD-L1 inhibitor and salts and crystalline forms thereof
JP2024513575A (ja) 2021-04-12 2024-03-26 インサイト・コーポレイション Ｆｇｆｒ阻害剤及びネクチン－４標的化剤を含む併用療法
AR126101A1 (es) 2021-06-09 2023-09-13 Incyte Corp Heterociclos tricíclicos como inhibidores de fgfr
WO2022261160A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
CN115960121B (zh) * 2022-10-27 2025-09-12 南通药明康德医药科技有限公司 一种合成1-(3-氧杂丁环烷基)-1h-吡唑-4-硼酸频哪醇酯的方法
KR20250135111A (ko) * 2024-03-05 2025-09-12 한국생명공학연구원 피리딘계 화합물을 유효성분으로 함유하는 염증성 질환 또는 자가면역질환의 예방 또는 치료용 약학적 조성물

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003066629A2 (en) 2002-02-06 2003-08-14 Vertex Pharmaceuticals Incorporated Heteroaryl compounds useful as inhibitors of gsk-3
GB0206860D0 (en) 2002-03-22 2002-05-01 Glaxo Group Ltd Compounds
JP4901102B2 (ja) * 2002-05-03 2012-03-21 エクセリクシス， インク． プロテインキナーゼモジュレーターおよびその使用方法
SE0202429D0 (sv) * 2002-08-14 2002-08-14 Astrazeneca Ab Novel Compounds
WO2004069160A2 (en) 2003-01-28 2004-08-19 Smithkline Beecham Corporation Chemical compounds
WO2004084813A2 (en) 2003-03-21 2004-10-07 Smithkline Beecham Corporation Chemical compounds
ATE492544T1 (de) 2004-08-26 2011-01-15 Pfizer Pyrazol-substituierte aminoheteroarylverbindungen als proteinkinasehemmer
JP4954086B2 (ja) 2004-12-08 2012-06-13 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー １ｈ−ピロロ［２，３−ｂ］ピリジン
DE602007004092D1 (de) 2006-03-22 2010-02-11 Vertex Pharma C-met-proteinkinasehemmer zur behandlung proliferativer erkrankungen
ES2340093T3 (es) 2006-06-22 2010-05-28 Biovitrum Ab (Publ) Derivados pirazina y piridina como inhibidores de cinasa mnk.
EP1900727A1 (en) 2006-08-30 2008-03-19 Cellzome Ag Aminopyridine derivatives as kinase inhibitors
GB0619342D0 (en) 2006-09-30 2006-11-08 Vernalis R&D Ltd New chemical compounds
GB0625659D0 (en) 2006-12-21 2007-01-31 Cancer Rec Tech Ltd Therapeutic compounds and their use
KR100979439B1 (ko) 2008-04-10 2010-09-02 한국화학연구원 신규 피라졸 및 벤즈옥사졸 치환된 피리딘 유도체 또는이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를유효성분으로 함유하는 이상세포 성장 질환의 예방 및치료용 약학적 조성물

Also Published As

Publication number Publication date
CL2008003188A1 (es) 2009-11-27
JP2011500778A (ja) 2011-01-06
IL205108A0 (en) 2010-11-30
EP2215085A2 (en) 2010-08-11
ATE523508T1 (de) 2011-09-15
CA2703653A1 (en) 2009-04-30
CN101910158A (zh) 2010-12-08
WO2009053737A3 (en) 2009-07-30
WO2009053737A2 (en) 2009-04-30
KR20100089090A (ko) 2010-08-11
PE20091116A1 (es) 2009-08-29
AU2008315746A1 (en) 2009-04-30
CO6270364A2 (es) 2011-04-20
TW200920367A (en) 2009-05-16
US20090118305A1 (en) 2009-05-07
MX2010004491A (es) 2010-06-21
UY31430A1 (es) 2009-05-29
EP2215085B1 (en) 2011-09-07
ECSP10010197A (es) 2010-06-29
US8017611B2 (en) 2011-09-13

Similar Documents

Publication Publication Date Title
AR069078A1 (es) Derivados de piridina y pirazina
AR033560A1 (es) Derivados de quinazolina, proceso para su preparacion, composicion farmaceutica, y su uso en la fabricacion de un medicamento,
AR074002A1 (es) Pirazolo e imidazopiridinilpirimidinaminas como inhibidores de la tirosina kinasa (igr-ir)
EA200971081A1 (ru) Пуриновые производные и их применение в качестве модуляторов толл-подобного рецептора 7
EA200702200A1 (ru) Дигидротиенопиримидины для лечения воспалительных заболеваний
EA200500018A1 (ru) Бензконденсированные гетероариламидные производные тиенопиридинов, применяемые в качестве терапевтических агентов, фармацевтические композиции, включающие их, и способы их применения
EA201070483A1 (ru) Новые офтальмологические композиции
AR045753A1 (es) Derivados de quinazolina, proceso de obtencion, uso y composiciones farmaceuticas.
AR066169A1 (es) Derivados de benzo-imidazoles, utiles para trastornos asociados con la actividad de dgat
EA200801998A1 (ru) ПИРИДИН[3,4-b]ПИРАЗИНОНЫ
TR201802944T4 (tr) İlaç olarak azai̇ndazol veya di̇azai̇ndazol türünün türevleri̇
AR039222A1 (es) Derivados de quinolina e isoquinolina, un metodo para su preparacion y su uso como inhibidores de la inflamacion
ATE517882T1 (de) Chinolinderivate
AR036598A1 (es) Derivados de 4,5-dihidro-1h-pirazol que tienen potente actividad antagonista de cb1
EA200870423A1 (ru) Производные триазолпиразинов, применимые в качестве противораковых агентов
EA201792046A1 (ru) Модуляторы рецептора андрогенов и их применение
AR045762A1 (es) Derivados de quinazolina
BR112013011580A2 (pt) derivados de ácido bisfenil pentanoico substituído por amino como inibidores de nep
EA200900924A1 (ru) Циклизованные производные как ингибиторы eg-5
AR051215A1 (es) Derivados de quinazolina
AR046452A1 (es) Derivados de quinazolina, metodos para su preparacion, composiciones farmaceuticas que los contienen y su uso como medicamento con efecto antiproliferativo
EA200802007A1 (ru) Соединения, потенцирующие рецептор амра, и применение указанных соединений в медицине
PE20081837A1 (es) Derivados de quinuclinidol como antagonistas de los receptores muscarinicos
PE20081703A1 (es) Nuevos derivados triciclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
EA201170722A1 (ru) Лактамы в качестве ингибиторов бета-секретазы

Legal Events

Date Code Title Description
FB Suspension of granting procedure